

Literaturverzeichnis

Hamburger Ärzteblatt 10 | 2016

Seite 1

Weidestr. 122 b
22083 Hamburg
Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

S. 12 – 16: Molekulare Onkologie und personalisierte Medizin – Vision und Wirklichkeit *Von Dr. Bernd Flath*

1. Diepgen P, Gruber G, Schadewaldt H. Der Krankheitsbegriff, seine Geschichte und Problematik, in: Büchner F. et al., Prolegomena einer Allgemeinen Pathologie. Berlin, Heidelberg, New York, 1969.
2. David H. Rudolf Virchow und die Medizin des 20. Jahrhunderts. München, 1993. 13ff.
3. Lennert K, et al. Histopathologie der Non-Hodgkin-Lymphome: Nach der aktualisierten Kiel-Klassifikation. Berlin, Heidelberg, New York, 1990.
4. Weinberg R A. Cancer: A genetic disorder, in: Mendelson J, et al. The molecular basis of cancer. Philadelphia, 2008.
5. Di Lonardo A, Nasio S, Pulciani S. Cancer: We should not forget the past. Journal of Cancer 2015;6: 29-39.
6. Hanahan D, Weinberg R.A. Hallmarks of cancer: The next generation. Cell 2011;144: 649-674.
7. Dutt P, Stambolic V. Oncogenes and tumor-suppressor genes, in: Tannock I, et al. The basic science of oncology. New York, Chicago, San Francisco, 2013.
8. Vogelstein B, et al. Cancer genome landscapes. Science 2013;339: 1546-1558.
9. Kampen K.R. The discovery and early understanding of leukemia. Leukemia Research 2012;36: 6-13.
10. Nowell PC. Discovery of the Philadelphia chromosome: a personal perspective. Journal of Clinical Investigation 2007;117: 2033-2035.
11. Hunter T. Treatment for chronic myelogenous leukemia: the long road to imatinib. Journal of Clinical Investigation 2007;117: 2036-2043.
12. Druker B.J., Translation of the Philadelphia chromosome into therapy for CML. Blood 2008;112: 4808-4817
13. Deininger M, et al. International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009, ASH Abstract 1126.
14. Kantarjian H, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012;119: 1981-1987.
15. Fukuoka M, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 Trial) Journal of Clinical Oncology 2003;21: 2237-2246.
16. Thatcher N, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicenter study (Iressa survival evaluation in lung cancer) Lancet 2005;366: 1527-1537.
17. Mok T, et al. Gefitinib or Carboplatin-Paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine 2009;361: 947-957.
18. Vargas A, et al. Biomarker development in the precision medicine era: lung cancer as a case study. Nature Reviews Cancer 2016;16: 523-537.
19. Joshua AM, Boutros PC, Kislinger T. Methods of molecular analysis, in: Tannock I, et al. The basic science of oncology. New York, Chicago, San Francisco, 2013.
20. Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharmaceutica Sinica B 2015;5:390-401.
21. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochimica Biophysica Acta 2010;1850: 105-117.
22. Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Molecular Oncology 2014;8: 1095-1111.
23. Lipinski K, et al. Cancer evolution and the limits of predictability in precision medicine. Trends in Cancer 2016;2: 49-

Literaturverzeichnis

Hamburger Ärzteblatt 10 | 2016

Seite 2

Weidestr. 122 b
22083 Hamburg
Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

24. Cheng F, Su L, Quian C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. *Oncotarget* 2016;7: 48832-48841.
25. Li Y, et al. A mini-review for cancer immunotherapy: molecular understanding of PD-1/PD-L1 pathway and translational blockade of immune checkpoints. *International Journal of Molecular Science* 2016;17: 1151 doi:10.3390/ijms17071151.
26. Borghaei H, et al. Nivolumab versus docetaxel in advanced nonsquamous no-small cell lung cancer. *New England Journal of Medicine* 2015;373: 1627-1639.
27. Györfy B, et al. Multigene prognostic tests in breast cancer: past, present, future. *Breast Cancer Research* 2015;17: 11 doi:10.1186/s13058-015-0514-2.
28. Eralp Y. The role of genomic profiling in breast cancer: the two faces of Janus. *Translational Oncogenomics* 2016, 8 (S1) 1-7.
29. Maio G. Chancen und Grenzen der personalisierten Medizin – eine ethische Betrachtung. *GGW- Das Wissenschaftsforum in Gesundheit und Gesellschaft* 2012;1: 15-19.
30. Tajik P, et al. Trial design for personalizing cancer care: a systematic review and classification. *Clinical Cancer Research* 2013;19: 4578-4588.
31. Hayes DF, Schott AF. Personalized medicine: genomic trials in oncology. *Transactions of the American Clinical and Climatological Association* 2015;126: 133-143.
32. Personalisierte Medizin – der Patient als Nutznießer oder Opfer? Tagungsdokumentation, Jahrestagung des Deutschen Ethikrates 2012. www.ethikrat.org/dateien/pdf/tagungsdokumentation-personalisierte-medizin.pdf

S. 28 - 29: Therapie der bikuspiden Aortenklappenerkrankung

Von PD Dr. Evaldas Girdauskas, Dr. Mathias Hillebrand, Prof. Dr. Yskert von Kodolitsch, Dr. Annika Jagodzinski, Prof. Dr. Jens Kubitz, Prof. Christian Detter, Prof. Dr. Stefan Blankenberg, Prof. Dr. Dr. Hermann Reichenspurner

1. Nistri S, Basso C, Marzari C, Mormino P, Thiene G. Frequency of bicuspid aortic valve in young male conscripts by echocardiogram. *Am J Cardiol* 2005;96:718-721.
2. Panayotova R, Macnab A, Waterworth PD. A pilot project of familial screening in patients with bicuspid aortic valve disease. *J Heart Valve Dis.* 2013;22:150-155.
3. Schievink WI, Raissi SS, Maya MM, Velebir A. Screening for intracranial aneurysms in patients with bicuspid aortic valve. *Neurology* 2010;74:1430-3.
4. Roberts CS, Roberts WC. Dissection of the aorta associated with congenital malformation of the aortic valve. *J Am Coll Cardiol* 1991;17:712-6.
5. Boodhwani M, de Kerchove L, Glineur D, Rubay J, Vanoverschelde JL, Noirhomme P, El Khoury G. Repair of regurgitant bicuspid aortic valves: a systematic approach. *J Thorac Cardiovasc Surg.* 2010;140:276-284.e1.
6. Svensson LG, Al Kindi AH, Vivacqua A, Pettersson GB, Gillinov AM, Mihaljevic T, Roselli EE, Sabik JF 3rd, Griffin B, Hammer DF, Rodriguez L, Williams SJ, Blackstone EH, Lytle BW. Long-term durability of bicuspid aortic valve repair. *Ann Thorac Surg.* 2014;97:1539-47.
7. Vohra HA, Whistance RN, De Kerchove L, Punjabi P, El Khoury G. Valve-preserving surgery on the bicuspid aortic valve. *Eur J Cardiothorac Surg.* 2013;43(5):888-98.

Literaturverzeichnis

Hamburger Ärzteblatt 10 | 2016

Seite 3

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

8. Aicher D, Fries R, Rodionychewa S, Schmidt K, Langer F, Schäfers HJ. Aortic valve repair leads to a low incidence of valve-related complications. *Eur J Cardiothorac Surg.* 2010;37:127-32.
9. Keane MG, Wiegers SE, Plappert T, Pochettino A, Bavaria JE, Sutton MG. Bicuspid aortic valves are associated with aortic dilatation out of proportion to coexistent valvular lesions. *Circulation.* 2000;102(19 Suppl 3):III35-9.
10. Ward C. Clinical significance of the bicuspid aortic valve. *Heart* 2000;83: 81–5.
11. Girdauskas E, Borger MA. Bicuspid aortic valve and associated aortopathy: an update. *Semin Thorac Cardiovasc Surg.* 2013;25(4):310-6.
12. Girdauskas E, Rouman M, Disha K, Espinoza A, Misfeld M, Borger MA, Kuntze T. Aortic Dissection After Previous Aortic Valve Replacement for Bicuspid Aortic Valve Disease. *J Am Coll Cardiol.* 2015;66(12):1409-11.
13. Pape LA, Tsai TT, Isselbacher EM, Oh JK, O'gara PT, Evangelista A, Fattori R, Meinhardt G, Trimarchi S, Bossone E, Suzuki T, Cooper JV, Froehlich JB, Nienaber CA, Eagle KA; International Registry of Acute Aortic Dissection (IRAD) Investigators. Aortic diameter \geq 5.5 cm is not a good predictor of type A aortic dissection: observations from the International Registry of Acute Aortic Dissection (IRAD). *Circulation* 2007;116:1120-7.
14. Rylski B, Branchetti E, Bavaria JE, Vallabhajosyula P, Szeto WY, Milewski RK, Desai ND. Modeling of predissection aortic size in acute type A dissection: More than 90% fail to meet the guidelines for elective ascending replacement. *J Thorac Cardiovasc Surg.* 2014;148:944-8.e1.

S. 30–31: Ursache Koronardissektion *Von Dr. Dr. Nursel Saritas*

1. Karsch KR, Haase KK, Mauser M, Völker W, Ickrath O, Seipel L. Perkutane transluminale coronare Eximer Laser Angioplastie. *Z Kardiol.* 1989;78:27.
2. Lichtlen P. Koronarspasmus während Koronarangiographie. 2. Auflage 363, 1990.
3. Rupperecht HJ, Erbel R, Brennecke R, Pop T, Jung D, Kottmeyer M, Hering R, Meyer J. Aktuelle Komplikationsrate der perkutanen transluminalen Koronarangioplastie bei stabiler und instabiler Angina. *Dtsch med Wschr.* 1988;113: 409.
4. Zeiher AM, Schächinger V, Weitzel SH, Wollschläger H, Just H. Intacoronary thrombus formation causes focal vasoconstriction of epicardial arteries in patients with coronary artery disease. *Circulation.* 1991;83:1519-1525.
5. Auch-Schwelk W. Koronarer Spasmus – ein klinisch relevantes Problem? *Herz.* 1998;23:106-115.
6. Düber C, Jungbluth A, Rumpelt HJ, Erbel R, Meyer J, Thoenes W. Morphology of the coronary arteries after combined thrombolysis and percutaneous transluminal coronary angioplasty for acute myocardial infarction. *Am J Cardiol.* 1986;58: 698-703.
7. Black AJR, Anderson HV, Ellis SG. Complications of coronary angiography Marcel Dekker, Inc. 1991.
8. Gerber T, Erbel R, Görge G, GJ, Rupperecht HJ, Meyer J. Classification of morphologic effects of percutaneous transluminal coronary angioplasty assessed by intravascular ultrasound. *Am J Cardiol.* 1992;70: 1546-1554.
9. Hamm CW, et al. *Clinical Research in Cardiology*, Volume 97, Number 8. 2008;475-51.

Literaturverzeichnis

Hamburger Ärzteblatt 10 | 2016

Seite 4

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekeh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

S. 34 – 35: Arbeiten in Überdruck *Von Dr. Karl P. Faesecke*

1. Senatsdrucksache Nr. 83, S.245-248 in: StAH Medizinal-Koll. II N 18 Bd. 1.
2. Monatsschreiben f. Unfallheilk. u. Invalidenw. 1909, 16, 17. S.1-13.
3. Heller R, Mager W, v.Schroetter H. Luftdruckerkrankungen mit besonderer Berücksichtigung der sogenannten Caissonkrankheit. Wien, 1900.
4. StAH Medizinal-Koll. II N 18 Bd.1, S.119-125.
5. StAH Medizinal-Koll. II N 18 Bd.1, S.76 b.
6. StAH Medizinal-Koll. II N18 Bd.2, S.14-18.
7. Boeremal, et.al. Leven zonder bloed. In: Arch.Chir.Neerl. 11, S. 70-82. 1959.
8. Schr. Medizinalamt an Prof. Deneke / AK.St.Georg v. 20.4.1909 in: StAH Medizinal-Koll. II N 18 Bd.2, S.19.